Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients

BACKGROUND: The DRCR.net Protocol T clinical trial assessed the comparative efficacy and safety of anti-VEGF treatments including aflibercept, ranibizumab and bevacizumab in diabetic macular edema (DME). Post -hoc analyses showed that after a 12-week induction period, there was still DME resolution...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Moreno, J. M., de Andrés-Nogales, F., Oyagüez, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500029/
https://www.ncbi.nlm.nih.gov/pubmed/32943041
http://dx.doi.org/10.1186/s12886-020-01637-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500029/
https://www.ncbi.nlm.nih.gov/pubmed/32943041
http://dx.doi.org/10.1186/s12886-020-01637-0

Ejemplares similares